Division of Urology, Department of Surgery, Western University, London, ON, Canada.
Life Kingsbury Hospital, Cape Town, South Africa.
Scand J Urol. 2020 Jun;54(3):215-219. doi: 10.1080/21681805.2020.1752795. Epub 2020 Apr 20.
MRI-guided transurethral ultrasound ablation (TULSA) is a novel modality for minimally invasive ablation in patients with localised prostate cancer (PCa). A multi-national Phase 1 (30 patients) and subsequent Phase 2 (115 patients) study showed TULSA to be feasible, safe and well tolerated. However, technical viability and safety of salvage prostatectomy for those who failed TULSA is unclear. Herein, we report the feasibility and morbidity of salvage radical prostatectomy (sRP) post-TULSA. Four patients with biopsy-proven residual cancer following TULSA underwent open retropubic sRP within 39 months of TULSA. Peri-and post-operative morbidity were reported. Detailed histopathologic assessment is reported. Median follow-up was 43 months after sRP. Mean operating times, blood loss, and length of stay were 210 min, 866 ml, and 3.5 days, respectively. Intraoperative finding of some fibrotic reaction of endopelvic and Denonvilliers fascia was characteristic. There were no perioperative complications. Whole-mount pathology sections showed one pT2b and three pT3a, suggesting under-staging pre-TULSA. Location of disease was compatible with persistent cancer mostly in the untreated peripheral safety region. One man received an artificial urinary sphincter. All men experienced erectile dysfunction responsive to treatment. Two patients with positive surgical margins had PSA progression requiring salvage radiation, with one requiring long-term androgen deprivation therapy. RP is a viable and safe salvage option if TULSA fails. Technical difficulty and perioperative morbidity were negligible and attributable to minimal peri-prostatic reaction from TULSA.
MRI 引导经尿道超声消融(TULSA)是一种治疗局限性前列腺癌(PCa)的新型微创消融方法。一项多中心的 1 期(30 例患者)和随后的 2 期(115 例患者)研究表明,TULSA 是可行的、安全的且耐受良好。然而,对于 TULSA 失败的患者,挽救性前列腺切除术的技术可行性和安全性尚不清楚。在此,我们报告 TULSA 后挽救性根治性前列腺切除术(sRP)的可行性和发病率。在 TULSA 后活检证实有残留肿瘤的 4 例患者,在 TULSA 后 39 个月内接受了开放式经耻骨后 sRP。报告了围手术期发病率。报告了详细的组织病理学评估。sRP 后中位随访时间为 43 个月。平均手术时间、出血量和住院时间分别为 210 分钟、866ml 和 3.5 天。术中发现一些盆内和 Denonvilliers 筋膜的纤维反应具有特征性。无围手术期并发症。全组织病理学切片显示 1 例 pT2b 和 3 例 pT3a,提示 TULSA 前分期不足。病变部位与治疗后外周安全区的未治疗区域的持续性癌症一致。1 例患者接受了人工尿道括约肌。所有男性均经历了勃起功能障碍,但经治疗后均可恢复。2 例切缘阳性的患者 PSA 进展,需要挽救性放疗,其中 1 例需要长期雄激素剥夺治疗。如果 TULSA 失败,RP 是一种可行且安全的挽救选择。技术难度和围手术期发病率可忽略不计,这与 TULSA 引起的前列腺周围反应轻微有关。